Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD

描述（由申请人提供）：本申请要求支持NIDA独立之路奖（K99 ROO），使David Herin博士能够发展独立研究职业所需的技能，研究药物滥用的药理学治疗。Herin博士拥有独特的经验和专业知识，这将是他发展成为一名独立研究人员的巨大财富。申请人在Kathryn Cunningham博士的博士前培训中建立了明确的临床前神经药理学专业知识。值得注意的是，他研究了药物治疗药物阻断精神兴奋剂对啮齿动物的行为和生理影响的能力。他对转化研究的兴趣使他在nida资助的药物开发部门（P50）寻求博士后奖学金，该部门由John Grabowski博士领导，在那里制定了一个完善的博士后计划，为Herin博士提供了临床研究的许多方面的培训。拟议的多学科研究计划的指导部分为Herin博士提供了在物质使用障碍临床试验的开发、实施和分析方面获得额外专业知识的机会，包括一项检查右旋安非他明治疗可卡因依赖和注意力缺陷多动障碍（ADHD）合并症患者能力的试点研究。此外，Herin博士将在这些研究的统计分析方面获得丰富的经验，并与部门教员合作进行正在进行的功能成像研究。培训将由具有临床试验设计、统计分析和功能成像专业知识的教师通过教学指导和个性化指导提供。这一多学科培训将最终实现大规模临床试验，评估右旋安非他明治疗ADHD共病和可卡因依赖的疗效。总之，拟议的培训将提供独特的、卓越的专业知识，使Herin博士能够作出重大的科学贡献，并在转化药物滥用研究方面开始成功的职业生涯。

DESCRIPTION (provided by applicant): This application requests support for a NIDA Pathway to Independence award (K99 ROO) enabling David Herin, Ph.D, to develop the skills necessary for an independent research career investigating pharmacological treatments for substance abuse. Dr. Herin possesses a unique combination of experience and expertise that will be a tremendous asset as he develops into an independent researcher. The applicant's predoctoral training with Dr. Kathryn Cunningham established clear expertise in preclinical neuropharmacology. Notably, he investigated the ability of pharmacotherapeutic agents to block the behavioral and physiological effects of psychostimulants in rodents. His interest in translational research led him to pursue a postdoctoral fellowship in the NIDA-funded medication development unit (P50) led by Dr. John Grabowski, where a well formulated post-doctoral plan provided training for Dr. Herin in many facets of clinical research. The mentored portion of the proposed multidisciplinary research plan provides Dr. Herin with the opportunity to gain additional expertise in development, implementation, and analysis of substance use disorder clinical trials, including a pilot study examining the ability of dextroamphetamine to treat individuals with comorbid cocaine dependence and attention-deficit hyperactivity disorder (ADHD). In addition, Dr. Herin will obtain extensive experience in statistical analysis of these studies, and collaborate with department faculty in ongoing functional imaging studies. Training will be provided via didactic instruction and individualized guidance from faculty members with expertise in clinical trial design, statistical analysis, and functional imaging. This multidisciplinary training will culminate in implementation of a large scale clinical trial assessing the efficacy of dextroamphetamine to treat comorbid ADHD and cocaine dependence. In all, the proposed training will provide a unique, exceptional expertise that will permit Dr. Herin to make significant scientific contributions and embark on a successful career in translational drug abuse research.